UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Lansoprazole

In Vitro Substrates

No substrate information.

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Substrate used	Cell System	Reference
ABCB1	MDR1, P-gp	Lansoprazole	62.8	Digoxin	Caco-2 cells	Pauli-Magnus, 2001
ABCC2	MRP2, cMOAT	Lansoprazole	>133	Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC3	MRP3	Lansoprazole	>133	Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC4	MRP4	Lansoprazole	>133	Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
SLC22A1	OCT1	Lansoprazole	35.8	Metformin	HEK293-OCT1	Nies, 2011
SLC22A2	OCT2	Lansoprazole	9.5	Metformin	HEK293-OCT2	Nies, 2011
SLC22A2	OCT2	Lansoprazole	3.28	Metformin	HEK293-OCT2	Hacker, 2015
ABCG2	BCRP, MXR	Lansoprazole	14.4	Methotrexate	BCRP membrane vesicles	Suzuki, 2009
SLC22A8	OAT3	Lansoprazole	0.4	Methotrexate	HEK293-OAT3	Narumi, 2017
SLC22A2	OCT2	Lansoprazole	13	Para-Aminosalicylic acid (PAS)	HEK293-OCT2	Parvez, 2017
SLC22A6	OAT1	Lansoprazole	4.13	Para-Aminosalicylic acid (PAS)	HEK293-OAT1	Parvez, 2017
SLC22A8	OAT3	Lansoprazole	2.18	Para-Aminosalicylic acid (PAS)	HEK293-OAT3	Parvez, 2017
ABCB11	BSEP	Lansoprazole	>133	Taurocholate	Sf9 cell membrane vesicles	Morgan, 2013

No drug-drug interaction information.